Skip to content
Search

Latest Stories

Previous Covid-19 infection substantially reduces risk of a new infection for 10 months: UCL study

Previous Covid-19 infection substantially reduces the risk of a new infection for up to 10 months afterwards, according to a study of care home residents and staff by University College London (UCL) scientists.

The study, published inThe Lancet on Thursday, found that care home residents who had been previously infected with Covid-19 were approximately 85 per cent less likely to be infected between October and February than those who had not been infected.


For staff, those with a past infection were around 60 per cent less likely to become infected again.

"It’s really good news that natural infection protects against reinfection in this time period. The risk of being infected twice appears to be very low," the study's lead researcher, Maria Krutikov of the UCL Institute of Health Informatics, said.

"The fact that prior Covid-19 infection gives a high level of protection to care home residents is also reassuring, given past concerns that these individuals might have less robust immune responses associated with increasing age."

The study involved 682 care home residents, with a median age of 86, and 1,429 staff in care homes. Tests conducted in June and July last year showed around a third were positive for the presence of coronavirus antibodies.

The study excluded the impact of vaccination by removing people 12 days following a first vaccine dose. The authors plan to look at vaccine effectiveness in a separate study.

Alexander Edwards, an associate professor in biomedical technology at the University of Reading who was not involved in the study, said there was still much uncertainty about the extent and duration of protection following infection.

"Reinfection does occur - so protection is not complete. We still expect natural infection should protect against more severe infection, but we still don't have enough data to know this," he said.

The researchers said the study period covered the emergence of the more contagious variant first identified in the UK and now known as Alpha, implying a good level of protection against that variant.

However, the concerning variant initially discovered in India and now designated the Delta variant has subsequently emerged and become dominant in Britain.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less